# Therapeutic Antibody for RSV IIB

> **NIH NIH R44** · TRELLIS BIOSCIENCE, INC. · 2020 · $1,000,000

## Abstract

Abstract
Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants, leading
annually to ~200,000 deaths and 3-4 million hospitalizations worldwide. Close to $1 billion has been invested by
the RSV community over the past two decades in clinical trials seeking to improve upon the marketed monoclonal
antibody Synagis®, which is only approved for prophylaxis of very low birth weight premature birth infants. None
of these efforts, which have attacked the same viral protein as Synagis (the F protein), has yielded a new
approved drug or vaccine. Based on insights into the pathology of RSV infection gained over the past ten years
by numerous investigators, Trellis has chosen to target the only other major viral envelope protein (the G protein).
Preclinical data support the expectation of substantially improved activity of Trellis’ monoclonal antibody TRL3D3
as a post-infection therapeutic, thereby addressing major populations not served by Synagis, including full-term
infants, the elderly and immunocompromised patients. With funding from an SBIR Phase II grant, Trellis has
established a commercially-attractive manufacturing process for TRL3D3. In this Phase IIB proposal, we seek
funding to complete the IND-enabling work and initiate production of the first clinical lot. We also propose to
explore the impact in mice of TRL3D3 on biomarkers that may have utility for establishing efficacy trends in early
clinical trials.

## Key facts

- **NIH application ID:** 9836793
- **Project number:** 5R44AI122360-04
- **Recipient organization:** TRELLIS BIOSCIENCE, INC.
- **Principal Investigator:** Lawrence Michael Kauvar
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,000,000
- **Award type:** 5
- **Project period:** 2016-02-01 → 2021-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9836793

## Citation

> US National Institutes of Health, RePORTER application 9836793, Therapeutic Antibody for RSV IIB (5R44AI122360-04). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9836793. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*